Skip to main content
Top
Published in: Molecular Cancer 1/2006

Open Access 01-12-2006 | Research

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery

Authors: Paula M De Angelis, Debbie H Svendsrud, Katherine L Kravik, Trond Stokke

Published in: Molecular Cancer | Issue 1/2006

Login to get access

Abstract

Background

Treatment of cells with the anti-cancer drug 5-fluorouracil (5-FU) causes DNA damage, which in turn affects cell proliferation and survival. Two stable wild-type TP53 5-FU-resistant cell lines, ContinB and ContinD, generated from the HCT116 colon cancer cell line, demonstrate moderate and strong resistance to 5-FU, respectively, markedly-reduced levels of 5-FU-induced apoptosis, and alterations in expression levels of a number of key cell cycle- and apoptosis-regulatory genes as a result of resistance development. The aim of the present study was to determine potential differential responses to 8 and 24-hour 5-FU treatment in these resistant cell lines. We assessed levels of 5-FU uptake into DNA, cell cycle effects and apoptosis induction throughout treatment and recovery periods for each cell line, and alterations in expression levels of DNA damage response-, cell cycle- and apoptosis-regulatory genes in response to short-term drug exposure.

Results

5-FU treatment for 24 hours resulted in S phase arrests, p53 accumulation, up-regulation of p53-target genes on DNA damage response (ATF3, GADD34, GADD45A, PCNA), cell cycle-regulatory (CDKN1A), and apoptosis-regulatory pathways (FAS), and apoptosis induction in the parental and resistant cell lines. Levels of 5-FU incorporation into DNA were similar for the cell lines. The pattern of cell cycle progression during recovery demonstrated consistently that the 5-FU-resistant cell lines had the smallest S phase fractions and the largest G2(/M) fractions. The strongly 5-FU-resistant ContinD cell line had the smallest S phase arrests, the lowest CDKN1A levels, and the lowest levels of 5-FU-induced apoptosis throughout the treatment and recovery periods, and the fastest recovery of exponential growth (10 days) compared to the other two cell lines. The moderately 5-FU-resistant ContinB cell line had comparatively lower apoptotic levels than the parental cells during treatment and recovery periods and a recovery time of 22 days. Mitotic activity ceased in response to drug treatment for all cell lines, consistent with down-regulation of mitosis-regulatory genes. Differential expression in response to 5-FU treatment was demonstrated for genes involved in regulation of nucleotide binding/metabolism (ATAD2, GNL2, GNL3, MATR3), amino acid metabolism (AHCY, GSS, IVD, OAT), cytoskeleton organization (KRT7, KRT8, KRT19, MAST1), transport (MTCH1, NCBP1, SNAPAP, VPS52), and oxygen metabolism (COX5A, COX7C).

Conclusion

Our gene expression data suggest that altered regulation of nucleotide metabolism, amino acid metabolism, cytoskeleton organization, transport, and oxygen metabolism may underlie the differential resistance to 5-FU seen in these cell lines. The contributory roles to 5-FU resistance of some of the affected genes on these pathways will be assessed in future studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shah MA, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001, 7: 2168-2181.PubMed Shah MA, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001, 7: 2168-2181.PubMed
2.
go back to reference Curtin NJ, Harris AL, Aherne GW: Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991, 51: 2346-2352.PubMed Curtin NJ, Harris AL, Aherne GW: Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991, 51: 2346-2352.PubMed
3.
go back to reference Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM: Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer. 2000, 36: 916-924. 10.1016/S0959-8049(00)00026-5CrossRefPubMed Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM: Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer. 2000, 36: 916-924. 10.1016/S0959-8049(00)00026-5CrossRefPubMed
4.
go back to reference Gottifredi V, Prives C: The S phase checkpoint: when the crowd meets at the fork. Semin Cell Dev Biol. 2005, 16: 355-368. 10.1016/j.semcdb.2005.02.011CrossRefPubMed Gottifredi V, Prives C: The S phase checkpoint: when the crowd meets at the fork. Semin Cell Dev Biol. 2005, 16: 355-368. 10.1016/j.semcdb.2005.02.011CrossRefPubMed
5.
go back to reference Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature. 2004, 432: 316-323. 10.1038/nature03097CrossRefPubMed Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature. 2004, 432: 316-323. 10.1038/nature03097CrossRefPubMed
6.
go back to reference Zhou BB, Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer. 2004, 4: 216-225. 10.1038/nrc1296CrossRefPubMed Zhou BB, Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer. 2004, 4: 216-225. 10.1038/nrc1296CrossRefPubMed
7.
go back to reference Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004, 10: 2158-2167. 10.1158/1078-0432.CCR-03-0362CrossRefPubMed Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004, 10: 2158-2167. 10.1158/1078-0432.CCR-03-0362CrossRefPubMed
8.
go back to reference Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55: 1407-1412.PubMed Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55: 1407-1412.PubMed
9.
go back to reference Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002, 1587: 194-205.CrossRefPubMed Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002, 1587: 194-205.CrossRefPubMed
10.
go back to reference De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke T: Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol. 2004, 24: 1279-1288.PubMed De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke T: Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol. 2004, 24: 1279-1288.PubMed
11.
go back to reference Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004, 73: 39-85. 10.1146/annurev.biochem.73.011303.073723CrossRefPubMed Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004, 73: 39-85. 10.1146/annurev.biochem.73.011303.073723CrossRefPubMed
12.
go back to reference Pizzorno G, Sun Z, Handschumacher RE: Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol. 1995, 49: 553-557. 10.1016/0006-2952(94)00444-QCrossRefPubMed Pizzorno G, Sun Z, Handschumacher RE: Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol. 1995, 49: 553-557. 10.1016/0006-2952(94)00444-QCrossRefPubMed
13.
go back to reference Takeda H, Haisa M, Naomoto Y, Kawashima R, Satomoto K, Yamatuji T, Tanaka N: Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line. Jpn J Cancer Res. 1999, 90: 677-684.CrossRefPubMed Takeda H, Haisa M, Naomoto Y, Kawashima R, Satomoto K, Yamatuji T, Tanaka N: Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line. Jpn J Cancer Res. 1999, 90: 677-684.CrossRefPubMed
14.
go back to reference Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene. 2001, 20: 1803-1815. 10.1038/sj.onc.1204252CrossRefPubMed Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene. 2001, 20: 1803-1815. 10.1038/sj.onc.1204252CrossRefPubMed
15.
go back to reference Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999, 104: 263-269.PubMedCentralCrossRefPubMed Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999, 104: 263-269.PubMedCentralCrossRefPubMed
16.
go back to reference Adimoolam S, Ford JM: p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA. 2002, 99: 12985-12990. 10.1073/pnas.202485699PubMedCentralCrossRefPubMed Adimoolam S, Ford JM: p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA. 2002, 99: 12985-12990. 10.1073/pnas.202485699PubMedCentralCrossRefPubMed
17.
go back to reference Shan B, Morris GF: Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53. Exp Cell Res. 2005, 305: 10-22. 10.1016/j.yexcr.2004.09.033CrossRefPubMed Shan B, Morris GF: Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53. Exp Cell Res. 2005, 305: 10-22. 10.1016/j.yexcr.2004.09.033CrossRefPubMed
18.
go back to reference Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q: p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem. 2004, 279: 21183-21192. 10.1074/jbc.M311912200CrossRefPubMed Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q: p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem. 2004, 279: 21183-21192. 10.1074/jbc.M311912200CrossRefPubMed
19.
go back to reference Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998, 188: 2033-2045. 10.1084/jem.188.11.2033PubMedCentralCrossRefPubMed Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998, 188: 2033-2045. 10.1084/jem.188.11.2033PubMedCentralCrossRefPubMed
20.
go back to reference Petak I, Tillman DM, Houghton JA: p53 dependence of Fas induction and acute apoptosis in response to 5-Fluorouracil-Leucovorin in human colon carcinoma cell lines. Clin Cancer Res. 2000, 6: 4432-4441.PubMed Petak I, Tillman DM, Houghton JA: p53 dependence of Fas induction and acute apoptosis in response to 5-Fluorouracil-Leucovorin in human colon carcinoma cell lines. Clin Cancer Res. 2000, 6: 4432-4441.PubMed
21.
go back to reference Larsen JK, Munch-Petersen B, Christiansen J, Jorgensen K: Flow cytometric discrimination of mitotic cells: resolution of M, as well as G1, S, and G2 phase nuclei with mithramycin, propidium iodide, and ethidium bromide after fixation with formaldehyde. Cytometry. 1986, 7: 54-63. 10.1002/cyto.990070108CrossRefPubMed Larsen JK, Munch-Petersen B, Christiansen J, Jorgensen K: Flow cytometric discrimination of mitotic cells: resolution of M, as well as G1, S, and G2 phase nuclei with mithramycin, propidium iodide, and ethidium bromide after fixation with formaldehyde. Cytometry. 1986, 7: 54-63. 10.1002/cyto.990070108CrossRefPubMed
22.
go back to reference Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T: Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype. Int J Cancer. 2005, 115: 935-942. 10.1002/ijc.20962CrossRefPubMed Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T: Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype. Int J Cancer. 2005, 115: 935-942. 10.1002/ijc.20962CrossRefPubMed
24.
go back to reference Quackenbush J: Microarray data normalization and transformation. Nat Genet. 2002, 32 (Suppl): 496-501. 10.1038/ng1032CrossRefPubMed Quackenbush J: Microarray data normalization and transformation. Nat Genet. 2002, 32 (Suppl): 496-501. 10.1038/ng1032CrossRefPubMed
Metadata
Title
Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
Authors
Paula M De Angelis
Debbie H Svendsrud
Katherine L Kravik
Trond Stokke
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2006
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-5-20

Other articles of this Issue 1/2006

Molecular Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine